Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2008

FAB Awarded SBIR Grant to Advance Cell-Free Protein Synthesis Platform

  • Fundamental Applied Biology (FAB) received $500,000 for the development of its cell-free protein synthesis technology toward commercialization. This SBIR phase IIB grant comes from the NSF.

    During the STTR phase I and phase II NSF projects, FAB reported that certain proteins could be made in a soluble form through a cell-free system that was controllable and efficient. With the current award, FAB will continue to develop the technology with a market-driven, therapeutic protein as FAB’s first target product.

    “The grant will allow FAB to further develop and optimize our cell-free technology to enable the production of pharmaceutical protein therapeutics with the goal of improving their biological activity,” says Daniel S. Gold, Ph.D., CEO.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »